GeoVax Labs, utilizing technology developed at Emory University, said it’s making progress with the AIDS vaccine it is developing.
The company reported what it called “successful human trial results” at a recent AIDS conference in Washington. The vaccines were well tolerated and stimulated anti-HIV/AIDS immune responses, according to Paul Goepfert at the University of Alabama-Birmingham. He is part of a group evaluating the GeoVax vaccine.
The results led to the scheduling of two more trials, which got underway in June, GeoVax said.
The trials are being conducted by the HIV Vaccine Trials Network. The group is funded and supported by the National Institutes of Health.